[46] The study also showed that CRVO treatment with an anti-VEGF agent used on a monthly basis for 6 months followed by PRN produces significantly better results in all end points compared with sham.

CervoMed Inc. (NASDAQ:CRVO – Get Free Report) has been assigned an average recommendation of “Hold” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports.

There remains some concern regarding the duration of treatment; laser remains a long-term solution to peripheral ischemia in CRVO. Other modalities, such as intravitreal steroids, surgical ...